<DOC>
	<DOCNO>NCT02521077</DOCNO>
	<brief_summary>This parallel-track , randomize study observe whether intravenous ascorbic acid reduces report fatigue woman receive adjuvant neo-adjuvant chemotherapy early stage breast cancer .</brief_summary>
	<brief_title>Intravenous Ascorbic Acid Women Receiving Adjuvant Neo-Adjuvant Chemotherapy Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status score â‰¤2 ; Diagnosed early stage breast cancer schedule receive either adjuvant neoadjuvant chemotherapy ; Willing receive either intravenous ascorbic acid normal saline ; Willing use acceptable contraceptive method duration study 30 day follow last dose study drug ; Negative urine serum pregnancy test within 2 week prior receipt study drug ; Willing complete evaluation tool ; Able give inform consent participate study ; Agree avoid additional supplemental ascorbic acid throughout study . Diagnosed Glucose6phosphate dehydrogenase deficiency ; Renal insufficiency ( Blood Urea Nitrogen &gt; 30 mg/dL , Creatinine &gt; 1.5 mg/dL ) ; Unwillingness mental incapacity complete selfreported questionnaire ; Active smoker ; Male sex</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Fatigue</keyword>
</DOC>